Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
Go back to Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting| (NASDAQ: XLO) | Delayed: 9.27 +0.22 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.05 | 52 Week High | $ | |||
| Open | $8.90 | 52 Week Low | $ | |||
| Day High | $9.54 | P/E | N/A | |||
| Day Low | $8.89 | EPS | $ | |||
| Volume | 155,563 | |||||
